The endocannabinoid system functions in part as a regulatory buffer for emotional responses to stress. It should therefore be no surprise that cannabinoids appear to help in post-traumatic stress syndrome.
There is hope that cannabinoids, and CBD in particular, can be effective against stress and generalised anxiety. Studies in animal models and with healthy human volunteers do suggest an anxiolytic-like effect with CBD, and CBD has been shown to reduce anxiety in patients with diagnosed social anxiety disorder.
ALS drugs need to include glutamate antagonists, anti-oxidants, centrally acting anti-inflammatory agents, microglial cell modulators, anti-apoptotic agents, neurotrophic growth factors, and mitochondria-enhancing agents. Cannabinoids appear to have activity in all of these areas.
The body’s endo-cannabinoid system has anti-inflammatory, antioxidant, and neurogenic capabilities of potential benefit to Alzheimer’s patients. Modulation of this system by pharmacological cannabinoids is emerging as a therapeutic goal.